title: A novel classification of lung cancer into molecular subtypes.
abstract: The remarkably heterogeneous nature of lung cancer has become more apparent over the last decade. In general, advanced lung cancer is an aggressive malignancy with a poor prognosis. The discovery of multiple molecular mechanisms underlying the development, progression, and prognosis of lung cancer, however, has created new opportunities for targeted therapy and improved outcome. In this paper, we define "molecular subtypes" of lung cancer based on specific actionable genetic aberrations. Each subtype is associated with molecular tests that define the subtype and drugs that may potentially treat it. We hope this paper will be a useful guide to clinicians and researchers alike by assisting in therapy decision making and acting as a platform for further study. In this new era of cancer treatment, the 'one-size-fits-all' paradigm is being forcibly pushed aside-allowing for more effective, personalized oncologic care to emerge.
authors.affiliation: CollabRx Inc., Palo Alto, California, United States of America.
authors.forename: Lisandra
authors.initials: L
authors.lastname: West
authors.forename: Smruti J
authors.initials: SJ
authors.lastname: Vidwans
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Campbell
authors.forename: Jeff
authors.initials: J
authors.lastname: Shrager
authors.forename: George R
authors.initials: GR
authors.lastname: Simon
authors.forename: Raphael
authors.initials: R
authors.lastname: Bueno
authors.forename: Phillip A
authors.initials: PA
authors.lastname: Dennis
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Otterson
authors.forename: Ravi
authors.initials: R
authors.lastname: Salgia
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016923:Cell Death / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification* / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D058889:Molecular Typing; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D019869:Phosphatidylinositol 3-Kinases; D066246:ErbB Receptors; D051057:Proto-Oncogene Proteins c-akt